Arcturus Therapeutics Holdings Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M |
| Operating expenses | $158.3M | $248.0M | $245.0M | $193.8M | $215.2M |
| Cash from operations | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M |
| Capital expenditure | $230,000 | $648,000 | $2.9M | $7.7M | $3.4M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M |
Shares outstanding 28.4M · Free float 94.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.